0.00
-28.57%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aditxt
Its shares trade under the ticker ADTX. It has been listed since 19 June 2020. In the fiscal year to 31 December 2025, it reported revenue of $3,195 and a net loss of $41.7m. At that date it held total assets of $16.5m and shareholders' equity of $5.6m.
ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The company is headquartered in Mountain View, California. The company went IPO on 2020-06-19. The firm is focused on developing technologies on improving the health of the immune system through immune reprogramming and monitoring. The Company’s immune reprogramming technology is at the pre-clinical stage and is designed to retrain the immune system to induce tolerance. The Company’s immune monitoring technology is designed to provide a personalized profile of the immune system. The firm is developing nucleic acid-based technology, Apoptotic DNA Immunotherapy (ADi) that mimics the way human body naturally induces tolerance to its tissues. The firm is developing Aditxt Immune Monitor (AiM), which provides a personalized comprehensive profile of the immune system.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Jun 2020
- Employees
- 26
- Website
- aditxt.com ↗
- Head office
- 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Amro AlbannaChairman of the Board, Chief Executive Officer, since 2017$500,000
- Mr. Thomas FarleyChief Financial Officer$464,616
- Ms. Rowena AlbannaChief Operating Officer
- Dr. Shahrokh ShabahangChief Innovation Officer, Director$325,000
- Ms. Corinne PankovcinChief Mergers and Acquisitions Officer$385,008
- Ms. Saundra PelletierDirector
- Mr. Brian BradyIndependent Director$3,855
- Ms. Sylvia HerminaIndependent Director
- Mr. Charles NelsonIndependent Director
- Dr. Jeffrey RungeIndependent Director$3,855
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ADiTx Therapeutics employs only two full-time staff members in Mountain View.
- The company focuses on nucleic acid-based technologies for organ transplant rejection.
- Apoptotic DNA Immunotherapy mimics natural human tissue tolerance induction mechanisms.
Weaknesses
- The firm has a very small workforce of just two employees.
- Immune reprogramming technology remains in the early pre-clinical development stage.
- Aditxt Immune Monitor provides profiles but lacks clinical validation data.
Opportunities
- Developing treatments for autoimmune diseases offers significant market expansion potential.
- Allergy therapies using immune reprogramming could address unmet medical needs.
- Personalized immune monitoring profiles may enhance patient-specific treatment strategies.
Threats
- Preclinical stage technologies face high risks of development failure.
- Limited employee count restricts operational capacity and research speed.
- Competitors in biotechnology may develop superior organ rejection solutions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.